27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Lineage Cell Therapeutics Inc (NYSE:LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC:RHHBY) Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy.
- Genentech will assume responsibility for further clinical development and commercialization of Lineage's OpRegen program.
- OpRegen is currently in a Phase 1/2a study in patients with advanced dry age-related macular degeneration with geographic atrophy.
- Related Link: Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements.
- Under the terms of the collaboration agreement, Lineage will complete activities related to the ongoing clinical study, complete enrollment, and perform certain manufacturing activities.
- Genentech will pay Lineage a $50 million upfront payment, and Lineage is eligible to receive up to $620 million in milestone payments and tiered double-digit royalties.
- Price Action: LCTX shares are up 13.7% at $2.41 during the premarket session on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!